Par Pharmaceutical to Market Three Rivers’ Ribavirin
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 26 (Table of Contents)
Published: 2 Jul-2002
DOI: 10.3833/pdr.v2002.i26.1040 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Par Pharmaceutical entered into an agreement with Three Rivers Pharmaceuticals to market and distribute ribavirin (Rebetol) a synthetic nucleoside analogue for the treatment of hepatitis C...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS